Literature DB >> 22476716

Which new diagnostics for tuberculosis, and when?

Frank Cobelens1, Susan van den Hof, Madhukar Pai, S Bertel Squire, Andrew Ramsay, Michael E Kimerling.   

Abstract

Recently, new diagnostic tools for tuberculosis detection and resistance testing have become available. The World Health Organization endorses new tuberculosis diagnostics by using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) process. This endorsement process takes place when limited evidence beyond test accuracy is available. There is a need to provide guidance to tuberculosis programs about which new diagnostics to scale up and how best to position them in diagnostic algorithms. To speed adoption of new diagnostics for tuberculosis, the policy recommendation process should be revised to consist of 2 steps: technical recommendation and programmatic recommendation. Technical recommendation would follow the GRADE process and be based on accuracy with limited cost and feasibility data, while programmatic recommendation would include patient-important outcomes, cost-effectiveness when implemented under routine conditions, and factors critical to successful scale-up. The evidence for both steps should be systematically collected, but each requires different study designs.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22476716     DOI: 10.1093/infdis/jis188

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  29 in total

1.  Promise versus reality: optimism bias in package inserts for tuberculosis diagnostics.

Authors:  Claudia M Denkinger; Jasmine Grenier; Jessica Minion; Madhukar Pai
Journal:  J Clin Microbiol       Date:  2012-05-09       Impact factor: 5.948

2.  Modeling the impact of alternative strategies for rapid molecular diagnosis of tuberculosis in Southeast Asia.

Authors:  Amanda Y Sun; Madhukar Pai; Henrik Salje; Srinath Satyanarayana; Sarang Deo; David W Dowdy
Journal:  Am J Epidemiol       Date:  2013-10-07       Impact factor: 4.897

Review 3.  Economic challenges associated with tuberculosis diagnostic development.

Authors:  Colleen F Hanrahan; Maunank Shah
Journal:  Expert Rev Pharmacoecon Outcomes Res       Date:  2014-04-28       Impact factor: 2.217

Review 4.  Diagnostic point-of-care tests in resource-limited settings.

Authors:  Paul K Drain; Emily P Hyle; Farzad Noubary; Kenneth A Freedberg; Douglas Wilson; William R Bishai; William Rodriguez; Ingrid V Bassett
Journal:  Lancet Infect Dis       Date:  2013-12-10       Impact factor: 25.071

Review 5.  Alignment of new tuberculosis drug regimens and drug susceptibility testing: a framework for action.

Authors:  William A Wells; Catharina C Boehme; Frank G J Cobelens; Colleen Daniels; David Dowdy; Elizabeth Gardiner; Jan Gheuens; Peter Kim; Michael E Kimerling; Barry Kreiswirth; Christian Lienhardt; Khisi Mdluli; Madhukar Pai; Mark D Perkins; Trevor Peter; Matteo Zignol; Alimuddin Zumla; Marco Schito
Journal:  Lancet Infect Dis       Date:  2013-03-24       Impact factor: 25.071

6.  Comparison of two methods for acquisition of sputum samples for diagnosis of suspected tuberculosis in smear-negative or sputum-scarce people: a randomised controlled trial.

Authors:  Jonathan G Peter; Grant Theron; Anil Pooran; Johnson Thomas; Mellissa Pascoe; Keertan Dheda
Journal:  Lancet Respir Med       Date:  2013-07-19       Impact factor: 30.700

Review 7.  Tuberculosis screening in high human immunodeficiency virus prevalence settings: turning promise into reality.

Authors:  E L Corbett; P MacPherson
Journal:  Int J Tuberc Lung Dis       Date:  2013-09       Impact factor: 2.373

Review 8.  Defining the needs for next generation assays for tuberculosis.

Authors:  Claudia M Denkinger; Sandra V Kik; Daniela Maria Cirillo; Martina Casenghi; Thomas Shinnick; Karin Weyer; Chris Gilpin; Catharina C Boehme; Marco Schito; Michael Kimerling; Madhukar Pai
Journal:  J Infect Dis       Date:  2015-04-01       Impact factor: 5.226

Review 9.  Target product profile of a molecular drug-susceptibility test for use in microscopy centers.

Authors:  Claudia M Denkinger; David Dolinger; Marco Schito; William Wells; Frank Cobelens; Madhukar Pai; Matteo Zignol; Daniela Maria Cirillo; David Alland; Martina Casenghi; Jim Gallarda; Catharina C Boehme; Mark D Perkins
Journal:  J Infect Dis       Date:  2015-04-01       Impact factor: 5.226

10.  Point-of-care testing for infectious diseases: diversity, complexity, and barriers in low- and middle-income countries.

Authors:  Nitika Pant Pai; Caroline Vadnais; Claudia Denkinger; Nora Engel; Madhukar Pai
Journal:  PLoS Med       Date:  2012-09-04       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.